Loss of striatal vesicular monoamine transporter protein (VMAT2) in human cocaine users

American Journal of Psychiatry

Volumn 160, Issue 1, 2003, Pages 47-55

  Little, Karley Y ^a,b   Krolewski, David M ^a,b   Zhang, Lian ^a,b   Cassin, Bader J ^a,b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ANTIBODY; BRAIN PROTEIN; COCAINE; DIHYDROTETRABENAZINE; DOPAMINE; TRITIUM; UNCLASSIFIED DRUG; VESICULAR MONOAMINE TRANSPORTER PROTEIN 2;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; AUTOPSY; BRAIN TISSUE; CLINICAL ARTICLE; COCAINE DEPENDENCE; CONTROLLED STUDY; DOPAMINE BRAIN LEVEL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; MALE; MOOD DISORDER; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DEPLETION;

ADOLESCENT; ADULT; ALCOHOLISM; BLOTTING, WESTERN; COCAINE-RELATED DISORDERS; CORPUS STRIATUM; DOPAMINE; FEMALE; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; NEUROPEPTIDES; REFERENCE VALUES; VESICULAR BIOGENIC AMINE TRANSPORT PROTEINS; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 0037223687     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.160.1.47     Document Type: Article

References (23)

1. Little KY, Zhang L, Desmond T, Frey KA, Dalack GW, Cassin BJ: Striatal dopaminergic abnormalities in human cocaine users. Am J Psychiatry 1999; 156:238-245
2. Wilson JM, Levey AI, Bergeron C, Kalasinsky K, Ang L, Peretti F, Adams VI, Smialek J, Anderson WR, Shannak K, Deck J, Niznik HB, Kish SJ: Striatal dopamine, dopamine transporter, and vesicular monoamine transporter in chronic cocaine users. Ann Neurol 1996; 40:428-439
3. Wilson JM, Kish SJ: The vesicular monoamine transporter, in contrast to the dopamine transporter, is not altered by chronic cocaine self-administration in the rat. J Neurosci 1996; 16:3507-3510
4. Borght V, Klibourn M, Desmond T, Kuhl D, Frey K: The vesicular monoamine transporter is not regulated by dopaminergic drug treatments. Eur J Pharmacol 1995; 194:577-583
5. Daniels DM, Amara SGUC: Regulated trafficking of the human dopamine transporter. J Biol Chem 1999; 274:35794-35801
6. Saunders C, Ferrer JV, Shi L, Chen J, Merrill G, Lamb ME, Leeb-Lundberg LM, Carvelli L, Javitch JA, Galli A: Amphetamine-induced loss of human dopamine transporter activity: An internalization-dependent and cocaine-sensitive mechanism. Proc Natl Acad Sci USA 2000; 97:6850-6855
7. Zhang L, Elmer LW, Little KY: Expression and regulation of the human dopamine transporter in a neuronal cell line. Mol Brain Res 1998; 59:66-73
8. Little KY, Elmer LW, Zhong H, Scheys JO, Zhang L: Cocaine induction of dopamine transporter trafficking to the plasma membrane. Mol Pharmacol 2002; 61:436-445
9. 3H]WIN 35428 binding sites in human striatum. Brain Res 1993; 628:17-25
10. Staley JK, Hearn L, Ruttenber J, Wetli CV, Mash DC: High affinity cocaine recognition sites on the dopamine transporter are elevated in fatal cocaine overdose victims. J Pharmacol Exp Ther 1994; 271:1678-1685
11. Peter D, Liu Y, Sternini C, de Giorgio R, Brecha N, Edwards RH: Differential expression of two vesicular monoamine transporters. J Neurosci 1995; 15:6179-6188
12. Hardy JA, Wester P, Backstrom I, Gottfries H, Oreland L, Stenstrom A, Winblad B: The regional distribution of dopamine and serotonin uptake and transmitters concentrations in the human brain. Neurochem Int 1987; 10:445-450
13. Hortnagl H, Schlogl E, Sperk G, Hornykiewicz O: The topographical distribution of the monoaminergic innervation in the basal ganglia of the human brain. Prog Brain Res 1983; 542:300-306
14. Beskow K, Gottfries CG, Roos BE, Winblad B: Determination of monoamine and monoamine metabolites in the human brain: Postmortem studies in a group of suicides and in a control group. Acta Psychiatr Scand 1976; 53:7-20
15. Little KY, Patel UN, Clark TB, Butts JD: Alteration of brain dopamine and serotonin levels in cocaine users: A preliminary report. Am J Psychiatry 1996; 153:1216-1218
16. Little KY, McLaughlin DP, Zhang L, McFinton PR, Dalack GW, Cook EH, Cassin BJ, Watson SJ: Brain dopamine transporter mRNA and binding sites in cocaine users: A post mortem study. Arch Gen Psychiatry 1998; 55:793-799
17. Staley JK, Talbot JZ, Ciliax BJ, Miller GW, Levey AI, Kung MP, Kung HF, Mash DC: Radioligand binding and immunoautoradiographic evidence for a lack of toxicity to dopaminergic nerve terminals in human cocaine overdose victims. Brain Res 1997; 747:219-229
18. Yeh SY, DeSouza EB: Lack of neurochemical evidence for neurotoxic effects of repeated cocaine administration in rats on brain monoamine neurons. Drug Alcohol Depend 1991; 27:41-61
19. Ryan LJ, Martone ME, Linder JC, Groves PM: Cocaine, in contrast to d-amphetamine, does not cause axonal terminal degeneration in neostriatum and agranular frontal cortex of Long-Evans rats. Life Sci 1988; 43:1403-1409
20. Kleven MS, Woolverton WL, Seiden LS: Lack of long-term monoamine depletions following repeated or continuous exposure to cocaine. Brain Res Bull 1988; 1:233-237
21. Hogan KA, Staa RG, Sonsalla PK: Analysis of VMAT2 binding after methamphetamine or MPTP treatment: Disparity between homogenates and vesicle preparations. J Neurochem 2000; 74:2217-2220
22. Kilbourn MR, Kuszpit K, Sherman P: Rapid and differential losses of in vivo dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) radioligand binding in MPTP-treated mice. Synapse 2000; 35:250-255
23. Schmitz JM, Stotts AL, Averill PM, Rothfleisch JM, Bailley SE, Sayre SL, Grabowski J: Cocaine dependence with and without comorbid depression: A comparison of patient characteristics. Drug Alcohol Dep 2000; 60:189-198